Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4275581 | 0.79 | CYP2D6 (0.32) | — | |
| SCHEMBL6182275 | 0.77 | MAPT (0.42) | — | |
| SCHEMBL4435637 | 0.74 | HSD11B1 (0.32) | — | |
| SCHEMBL6134036 | 0.73 | USP2 (0.43) | — | |
| SCHEMBL6697462 | 0.73 | L3MBTL1 (0.33) | — | |
| Hydrochloric Acid SCHEMBL2149437 | 0.72 | GNAO1 (0.43) | CES2FAAH | |
| Trifluoroacetic Acid SCHEMBL6134916 | 0.71 | FUCA1 (0.35) | CES2FAAH | |
| SCHEMBL6134978 | 0.71 | LIPG (0.43) | CES2FAAH | |
| SCHEMBL27797658 | 0.71 | — | — | |
| SCHEMBL5559590 | 0.71 | CYP2D6 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| WO-2004113368-A1 | CYCLIC LIPOPEPTIDES | ASTELLAS PHARMA INC. (JP) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004014-A1 | Fungicides, microbiocides; glucanase inhibitor; prophylaxis, therapy for pneumocystis infections in humans, animals | MAN2B1, MAN2A1, MANBA | CES2 616/4885FAAH 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.